

CC (e.g. HIV, hepatitis A, B or C), fungal or protozoan pathogens. This sequence represents a staphylococcal protein relating to the method for identifying and producing pathogen specific antigens of the invention

XX Sequence 645 AA;

Query Match 99.8%; Score 2295; DB 6; Length 645;
Best Local Similarity 100.0%; Pred. No. 6 4e-142; Indels 0; Gaps 0;
Matches 445; Conservative 0; Mismatches 0;

Qy	2 ABETGANTNTAQPCKPDEAVASPTTSEKAPTPKPVANAVSVNSNKETPAPTSRTKEAKEVKE 61
Db	42 ABETGANTNTAQPCKPDEAVASPTTSEKAPTPKPVANAVSVNSNKETPAPTSRTKEAKEVKE 101
Qy	62 VRAPKETKETKPAAKNTTNPILQELRFAIKRPAKIDKQDHSAPNSRPIDEEMKEDGT 121
Db	102 VRAPKETKETKPAAKNTTNPILQELRFAIKRPAKIDKQDHSAPNSRPIDEEMKEDGT 161
Qy	122 QQFYHVASVSPARVIFTDSKPEIELGQGQFWRKXVIEGQKELFIRKLYSDYKDYA 181
Db	162 QQFYHVASVSPARVIFTDSKPEIELGQGQFWRKXVIEGQKELFIRKLYSDYKDYA 221
Qy	182 YIRFSVSYNGTAKVIVSTHNNAKCEKVDYTAQPIYNSADKFTTEEDYKACLLAP 241
Db	222 YIRFSVSYNGTAKVIVSTHNNAKCEKVDYTAQPIYNSADKFTTEEDYKACLLAP 281
Qy	242 YKKAKTLEEROYELNKQDQKULPECKSKAKEYKLEDTYKALDQVKSAITFQVQPTNEK 301
Db	282 YKKAKTLEEROYELNKQDQKULPECKSKAKEYKLEDTYKALDQVKSAITFQVQPTNEK 341
Qy	302 MELDQTKVYESTENNESEMDTEYKFKFTGNGKCNVPTSTNDYKDFMVEGQR 361
Db	342 MELDQTKVYESTENNESEMDTYYKFKFTGNGKCNVPTSTNDYKDFMVEGQR 401
Qy	362 VATISKDAQNTTTFIIPYEGKTHYDAVTKVHCVIDEGYKAVVIVDKRAFTKNTDK 421
Db	402 VRTISKDAQNTTTFIIPYEGKTHYDAVTKVHCVIDEGYKAVVIVDKRAFTKNTDK 461
Qy	422 SNKKEQDQNSXAKCETATPSPKTP 446
Db	462 SNKKEQDQNSXAKCETATPSPKTP 486

SEQ ID NO. 1.

RESIDUE 3 ABJ19106 standard; protein: 645 AA.
ID ABJ19106
XX ABJ19106
AC ABJ19106
XX DT 06-MAR-2003 (first entry)
XX Pathogen specific antigen related staphylococcal protein SEQ ID No 414.
DB Antibacterial; virucide; fungicide; protozoicide; cytotoxic; anti-HIV;
XX hyperimmune; serum-reactive; antigen; pathogen; tumour; allergen;
XX auto-immune; immunity; vaccine; staphylococcal infection; antibody; cancer;
XX autoimmune disease; HIV; hepatitis.
OS Staphylococcus sp.
XX PN WO200259148-A2.
XX PD 01-AUG-2002.
XX PF 21-JAN-2002; 2002WO-EP000546.
XX PR 26-JAN-2001; 2001AT-00000130.
XX PA (CISr) CITEM BIOTECHNOLOGIES GMbH.
XX PI Meinke A, Nagy E, Von Ahsen U, Klade C, Henics T, Zauner W,
PI Minh DB, Vytvytska O, Etz H, Dryla A, Weichhart T, Hafner M;
PI Tempelmaier B;
XX DR WPI: 2003-075410/07.
XX PT Identifying, isolating and producing hyperimmune serum-reactive antigens
PT from a pathogen, for preparing vaccine or medicament for treating or
PT preventing e.g. staphylococcal infections, comprising providing antibody
PT preparation.

XX Example 7: Page 220; 252pp; English.
XX The invention relates to a novel method for identifying, isolating and
CC producing hyperimmune serum-reactive antigens from a pathogen, tumour
CC or allergen, a tissue or host prone to autoimmunity, where the antigens are
CC used in a vaccine, comprises providing antibody preparation from a plasma
CC pool of a type of animal, or individual sera with antibodies against the
CC specific pathogen, tumour, allergen, tissue or host prone to auto-
CC immunity. The hyperimmune serum-reactive antigens comprising any of the
CC 62 sequences of 53-2261 amino acids fully defined in the specification,
CC or their hyperimmune fragments are useful for the manufacture of a
CC pharmaceutical preparation, particularly a vaccine against staphylococcal
CC infections or colonisation against *S. aureus* or *S. epidermidis*. The
CC preparation of antibodies is useful for the manufacture of a medicament
CC for treating or preventing staphylococcal infections or colonisation
CC against *S. aureus* or *S. epidermidis*. The antibody preparations may also
CC be used for diagnostic and imaging purposes. Other conditions that can be
CC treated include cancer, autoimmune diseases or infections caused by viral